国际眼科纵览

• 综述 •    下一篇

抗血管内皮生长因子治疗视网膜静脉阻塞继发黄斑水肿的研究进展

张志纯  汪浩   

  1. 200072上海市第十人民医院眼科
  • 收稿日期:2016-06-27 出版日期:2016-10-22 发布日期:2016-10-25
  • 通讯作者: 汪浩,Email:whpp_cn@live.cn

Research progress of anti-vascular endothelial growth factor for macular edema secondary to retinal vein occlusion

ZHANG Zhi-chun, WANG Hao.   

  1. Department of Ophthalmology, Shanghai Tenth People’s Hospital, Shanghai 200072, China
  • Received:2016-06-27 Online:2016-10-22 Published:2016-10-25
  • Contact: WANG Hao, Email:whpp_cn@live.cn

摘要:

黄斑水肿是导致视网膜静脉阻塞患者视力下降及影响预后的主要因素之一,目前治疗方法除传统黄斑格栅样光凝外,还包括糖皮质激素类药物、抗血管内皮生长因子(VEGF)药物以及玻璃体视网膜手术等,其中抗VEGF药物因其效果可靠、并发症少等优势而被广泛应用,但需反复注射以及黄斑水肿复发问题仍未得到解决,抗VEGF药物的个体化治疗方式以及与其它治疗方法联合应用为降低治疗黄斑水肿的医疗成本提供新的思路。(国际眼科纵览, 2016,  40:  289-294)

Abstract:

Macular edema is one of main reason that lead to visual loss and poor visual prognosis of patients with retinal vein occlusion. Current treatment options for macular edema include grid laser treatment, intravitreal injection of steroids, surgical procedures and intravitreal anti-vascular endothelial growth factor (VEGF) agents. Anti-VEGF agents have been wide used in the treatment of various forms of macular edema, due to their reliable effect and less complications. However, repeatedly treatment and recurrence of macular edema have not been resolved. Individual treatment and combination therapy provide new ideas for reducing the cost of medical treatment for macular edema.  (Int Rev Ophthalmol, 2016, 40: 289-294)